United States Breast Cancer Therapeutics Market, By Therapy {Chemotherapy (Anthracyclines, Taxanes, Antimetabolites, and Others), Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Others), Immunotherapy, Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, and Others), and Others}, By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others), and By Region, Competition, Forecast & Opportunities, 2028

United States breast cancer therapeutics market is expected to grow at an impressive rate during the forecast period. The rising incidence of breast cancer, improvements in cancer biology and pharmacology that support treatment development, rising R&D investment, the introduction of several diagnostic and screening programs, and favorable insurance and reimbursement policies contribute to the growth of the market.

Over the past few decades, the incidence of breast cancer has been steadily rising, primarily because of aging population and altering lifestyles. The prevalence of breast cancer is also increasing as a result of hereditary and environmental factors, including obesity, sedentary behavior, and exposure to specific chemicals. The market for breast cancer therapeutics is expanding as a result of the rise in the incidence of breast cancer, which is driving the demand for more effective and cutting-edge treatments.

Due to the vast number of therapeutics in development, the market for breast cancer therapeutics is predicted to expand significantly over the next few years. Immune checkpoint inhibitors, antibody-drug conjugates, and bispecific antibodies are a few of the innovative medicines and therapy approaches that are currently being created for the treatment of breast cancer. The United States breast cancer therapeutics market will grow even more as a result of the effective development and approval of these treatments.

In the United States, around 264,000 cases of breast cancer are discovered in women each year and 2,400 cases have been reported in men, according to the Centers for Disease Control and Prevention (CDC). In the United States, breast cancer claims the lives of over 42,000 women and 500 men annually.

However, several unfavorable drug side effects and the high price of therapeutics have negatively impacted the growth of the United States breast cancer therapeutics market. Concerns have been stated regarding the increased risk of chronic & acute consequences among breast cancer patients due to the negative effects of chemotherapy. These chemotherapy patients typically suffer from problems such as heart toxicity, pneumonitis, arm lymphedema, neuropathy, and skin problems.

Additionally, the adjuvant therapy can cause neutropenia, radiation dermatitis, fatigue, and other side effects. The numerous side effects connected with breast cancer treatments may restrict the use of therapy and impede market expansion.

In the treatment of breast cancer, immunotherapy, a new area in oncology, has produced encouraging results. Immunotherapies, including immune checkpoint inhibitors, have been demonstrated to be helpful in treating some forms of breast cancer, which, in turn, will increase their use in the coming years. Immune checkpoint inhibitors function by provoking the immune system to combat cancer cells. The United States breast cancer therapeutics market is anticipated to grow during the next few years due to the rising use of immunotherapies.

The goal of precision medicine is to determine the specific genetic alterations that are causing cancer in patients. This is done using genetic testing and other molecular diagnostic methods. As a result, more specialized and tailored treatment alternatives can be created. The development of novel, more potent breast cancer treatments is anticipated to be fueled by the increased emphasis on precision medicine.

A healthcare strategy known as patient-centric care puts the patient's unique requirements, preferences, and values first. More patient-friendly breast cancer therapies are anticipated to be developed as the importance placed on patient-centered care increases. For instance, the creation of at-home oral medicines is anticipated to enhance patients' quality of life by lowering the frequency of hospital visits.

Scorpion Therapeutics, Inc. (Scorpion), a cutting-edge clinical-stage oncology company that is redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, announced that the first patient has been dosed in a Phase 1/2 first-in-human dose escalation and expansion clinical trial evaluating STX-478, Scorpion's highly unique, allosteric, and central nervous-system (CNS) penetrant mutant phosphoinositide-3-kinase alpha (“PI3Kα”), for the treatment of HR+/HER2- breast cancer and other solid tumors. In the Phase 1/2 clinical trial, STX-478 will be examined both alone and in combination with other approved drugs in patients with HR+/HER2- breast cancer. These solid tumors include head and neck squamous cell carcinoma (HNSCC), gynecological and breast cancers, and others.

Improvements in Cancer Biology and Pharmacology that Support Treatment Development

The United States breast cancer therapeutics market is expected to grow in the coming years due to advancements in cancer biology and pharmacology that assist therapy development. New and more potent treatments for breast cancer are being created as scientists and researchers continue to understand the biology and pharmacology of cancer. The development of personalized medicine, combination therapy, targeted therapies, and improvements in drug delivery are a few of the developments in cancer biology and pharmacology which are propelling the market's expansion.

An innovative targeted therapy for difficult-to-treat advanced breast tumors was authorized by the Food and Drug Administration. Research and campaigns from the lab of Donald McDonnell, PhD, Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology at the Department of Pharmacology and Cancer Biology, were vital to its development. The entirely novel medication elacestrant occupies an important void in the market. It is the first and only medication authorized particularly to treat breast tumors with mutations in the ESR1 estrogen receptor, which are resistant to conventional endocrine therapy. According to a press statement from the drug's creator, these mutations can be found in up to 40% of advanced or metastatic breast tumors that test positive for the estrogen receptor but negative for the HER2 receptor. Thus, the United States breast cancer therapeutics market is anticipated to grow due to the enhancements in cancer biology and pharmacology. 

Download Free Sample Report

Growing Incidences of Breast Cancer

In the United States, breast cancer is one of the most prevalent cancers that affect women, and its prevalence has increased recently. Numerous factors, such as changes in lifestyle, aging population, and inheritance have led to an increase in the incidence of breast cancer. The likelihood of acquiring breast cancer has increased as sedentary lifestyles and unhealthy diets have become increasingly common. The risk of acquiring breast cancer also rises with population aging.

Additionally, more women are undergoing screening and diagnosis due to the growing awareness of breast cancer and the value of early detection, which is fueling the demand for breast cancer therapeutics. Treatment of breast cancer requires early detection, and the availability of efficient therapies can greatly enhance patient outcomes.

The United States breast cancer therapeutics market is anticipated to grow to meet the rising need for effective treatments as the incidence of breast cancer will increase in the coming years.

Introduction of Several Diagnostic and Screening Programs

Programs for diagnosis and screening are essential for identifying breast cancer at an early stage. The key to successfully treat breast cancer is early detection. The United States has implemented a number of diagnostic and screening initiatives to boost breast cancer's early detection rate. Mammography, clinical breast examination, breast self-examination, and genetic testing are among these programs.

The most used breast cancer screening method is mammography. A low-dose x-ray can identify breast cancer early or before any symptoms manifest. A healthcare expert physically examines breasts during a clinical breast exam. Women can perform a breast self-examination on their own to find any anomalies in their breasts. Women who have inherited DNA mutations that enhance their risk of breast cancer are found through genetic testing.

In the next years, the market for breast cancer medicines in the United States is anticipated to expand in response to the rising need for efficient treatments, which is being influenced by the implementation of numerous diagnostic and screening programs. The outcomes for breast cancer patients can be considerably improved by the availability of efficient treatments. The quality of life and outcomes for breast cancer patients are expected to be significantly improved by the United States breast cancer therapeutics market during the forecast period.

Market Segmentation

The United States breast cancer therapeutics market can be segmented by therapy, end user, and region. By therapy, the United States breast cancer therapeutics market can be segmented into chemotherapy, hormone therapy, immunotherapy, targeted therapy, and others. Based on chemotherapy, the United States breast cancer therapeutics market is divided into anthracyclines, taxanes, antimetabolites, and others. Based on hormone therapy, the United States breast cancer therapeutics market is divided into selective estrogen receptor modulators, aromatase inhibitors, and others. Based on targeted therapy, the United States breast cancer therapeutics market is divided into monoclonal antibodies, tyrosine kinase inhibitor, herceptin, and others. Based on end user, the United States breast cancer therapeutics market is divided into hospitals, specialty clinics, ambulatory surgical centers, and others.

 Market Players

AstraZeneca PLC, Eli Lilly and Company, Genentech, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Seattle Genetics, Inc. are among others some of the leading companies operating in the United States breast cancer therapeutics market.

·         United States Breast Cancer Therapeutics Market, By Therapy

o    Chemotherapy

o    Hormone Therapy

o    Immunotherapy

o    Targeted Therapy

o    Others

·         United States Breast Cancer Therapeutics Market, By Chemotherapy Drugs

o    Anthracyclines

o    Taxanes

o    Antimetabolites

o    Others

·         United States Breast Cancer Therapeutics Market, By Hormone Therapy

o    Selective Estrogen Receptor Modulators

o    Aromatase Inhibitors

o    Others

·         United States Breast Cancer Therapeutics Market, By Targeted Therapy

o    Monoclonal Antibodies

o    Tyrosine Kinase Inhibitor

o    Herceptin

o    Others

·         United States Breast Cancer Therapeutics Market, By End User

o    Hospitals

o    Specialty Clinics

o    Ambulatory Surgical Centers

o    Others

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the United States breast cancer therapeutics market

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

United States Breast Cancer Therapeutics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]